Latest Institutional Placement News

Page 3 of 64
FireFly Metals has outlined a 4.6Mtpa Green Bay development case with an after-tax NPV of A$3.0 billion, while lifting resource confidence and ending the quarter with A$337.1 million in cash. The next test is whether the preliminary study can survive feasibility work, permitting and project financing.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Kaoko Metals has expanded its Chalkos exploration campaign to at least 15,000 metres after maiden drilling confirmed broad, shallow copper-silver mineralisation at Otniel. A $20 million placement leaves the ASX-listed explorer with $22.0 million in cash to fund the next phase, but the discovery remains at an early exploration stage.
Maxwell Dee
Maxwell Dee
29 Oct 2026
Medallion Metals has moved Ravensthorpe into mine development and is preparing Cosmic Boy for gold processing, backed by approximately $175 million in available liquidity. The September quarter also delivered high-grade drilling extensions and major construction progress, but commissioning and execution now carry the story.
Maxwell Dee
Maxwell Dee
29 Oct 2026
L1 Global Long Short Fund has completed its entitlement offer, shortfall offers and institutional placement, raising the maximum A$565.4 million available. The capital will be invested under the L1 Global Long Short Strategy, with 321.2 million new shares due to begin trading next week.
Claire Turing
Claire Turing
27 Oct 2026
Minerals 260 has strengthened the funding and development position of its Bullabulling gold project, reporting approximately A$600 million of pro forma cash and a definitive feasibility study still targeted for Q1 2027. The company has also completed initial grade-control drilling, expanded its mining tenure and advanced village and water infrastructure.
Maxwell Dee
Maxwell Dee
27 Oct 2026
Brazilian Critical Minerals has moved its Ema rare earth project into FEED, raised approximately A$10 million and advanced the final land-access step for environmental licensing. Its proposed acquisition of a Brazilian magnesium sulphate plant could cover half of Ema’s early reagent needs, but remains subject to approvals, restructuring and plant modifications.
Maxwell Dee
Maxwell Dee
27 Oct 2026
GR Engineering Services delivered stronger FY26 earnings and lifted its dividend, but the scale of its new project pipeline is bringing a substantial working-capital requirement. The ASX-listed contractor is forecasting FY27 revenue of A$825 million to A$850 million after securing more than A$1 billion in contracts since April.
Victor Sage
Victor Sage
26 Oct 2026
NH3 Clean Energy has expanded the potential market for its WAH2 clean ammonia project and completed key environmental surveys, but now expects to make its final investment decision in 2027 rather than 2026. The company ended September with A$4.404 million in cash after raising A$4 million from predominantly institutional investors.
Victor Sage
Victor Sage
26 Oct 2026
Echo IQ’s FDA-cleared EchoSolv AS platform processed 9,697 full-result assessments in the September quarter, while the company ended the period with A$107.8 million in cash. The stronger balance sheet gives it room to pursue US enterprise deployments, but commercial conversion and the unresolved EchoSolv HF regulatory pathway remain the key tests.
Victor Sage
Victor Sage
26 Oct 2026
Titomic has secured approval for a US$10.3 million direct loan from the US Export-Import Bank to fund a high-pressure cold-spray production cell in Huntsville, Alabama. The project is expected to expand US manufacturing capacity and support at least dozens of full-time jobs.
Victor Sage
Victor Sage
22 Oct 2026
Felix Group has completed its shareholder purchase plan, raising A$0.1 million at A$0.038 a share and issuing 2.82 million new shares. The broader equity raising could reach A$5.65 million, but its final size still depends on shareholder approval of the institutional placement’s second tranche.
Victor Sage
Victor Sage
21 Oct 2026
Percheron Therapeutics has secured a funded path towards a Vanderbilt Health-led HMBD-002 trial in high-risk AML and MDS, while ending September with $4.875 million in cash. The biotechnology company also installed a new chief executive and began a preclinical combination study with Invion.
Ada Torres
Ada Torres
20 Oct 2026

Browse the archive

Full archive